Immunotherapy as a Neoadjuvant Strategy in Liver Transplantation for Hepatobiliary Carcinoma

M. Abdelrahim; A. Esmail; B. Khasawneh; E. Al-Najjar

doi:10.1016/j.hpb.2025.07.260

Immunotherapy as a Neoadjuvant Strategy in Liver Transplantation for Hepatobiliary Carcinoma

M. Abdelrahim, A. Esmail, B. Khasawneh, E. Al-Najjar

Research output: Contribution to journal › Article › peer-review

Abstract

Hepatobiliary Carcinoma (HBC) ranks as the sixth most prevalent cancer worldwide. This study reports our institutional experience in patients with HBC who had received Immune Checkpoint Inhibitors (ICPI) prior to curative OLT.

Original language	English (US)
Pages (from-to)	S364-S365
Journal	HPB
Volume	27
DOIs	https://doi.org/10.1016/j.hpb.2025.07.260
State	Published - 2025

Divisions

Medical Oncology

Access to Document

10.1016/j.hpb.2025.07.260

Cite this

@article{643dd060a18e4954b488411caa8e1c21,

title = "Immunotherapy as a Neoadjuvant Strategy in Liver Transplantation for Hepatobiliary Carcinoma",

abstract = "Hepatobiliary Carcinoma (HBC) ranks as the sixth most prevalent cancer worldwide. This study reports our institutional experience in patients with HBC who had received Immune Checkpoint Inhibitors (ICPI) prior to curative OLT.",

author = "M. Abdelrahim and A. Esmail and B. Khasawneh and E. Al-Najjar",

note = "doi: 10.1016/j.hpb.2025.07.260",

year = "2025",

doi = "10.1016/j.hpb.2025.07.260",

language = "English (US)",

volume = "27",

pages = "S364--S365",

journal = "HPB",

issn = "1365-182X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Immunotherapy as a Neoadjuvant Strategy in Liver Transplantation for Hepatobiliary Carcinoma

AU - Abdelrahim, M.

AU - Esmail, A.

AU - Khasawneh, B.

AU - Al-Najjar, E.

N1 - doi: 10.1016/j.hpb.2025.07.260

PY - 2025

Y1 - 2025

N2 - Hepatobiliary Carcinoma (HBC) ranks as the sixth most prevalent cancer worldwide. This study reports our institutional experience in patients with HBC who had received Immune Checkpoint Inhibitors (ICPI) prior to curative OLT.

AB - Hepatobiliary Carcinoma (HBC) ranks as the sixth most prevalent cancer worldwide. This study reports our institutional experience in patients with HBC who had received Immune Checkpoint Inhibitors (ICPI) prior to curative OLT.

U2 - 10.1016/j.hpb.2025.07.260

DO - 10.1016/j.hpb.2025.07.260

M3 - Article

SN - 1365-182X

VL - 27

SP - S364-S365

JO - HPB

JF - HPB

ER -

Immunotherapy as a Neoadjuvant Strategy in Liver Transplantation for Hepatobiliary Carcinoma

Abstract

Divisions

Access to Document

Fingerprint

Cite this